Veru Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for VERU, updated each market day.
VERU AI Sentiment
AI sees no strong directional signal for Veru Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Sector
Exchange
Market Cap
$39,002,277
Cap Tier
Employees
20
Headquarters
MIAMI, FL
Listed Since
June 1, 1990
Website
VERU Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VERU Volatility
Veru Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
